Medwire 
(11/23, Grasmo) reported that "research findings published in the International Journal of Clinical Oncology suggest that temsirolimus effectively stabilizes disease progression in patients with metastatic renal cell carcinoma (mRCC) undergoing hemodialysis." According to the article, "temsirolimus, a novel specific inhibitor of mammalian target of rapamycin, has previously been shown to exhibit an inhibitory effect on tumor cell growth and demonstrated significant overall and progression-free survival benefits compared with interferon (IFN)-alpha in patients with untreated poor-prognosis mRCC." Medwire noted that "the findings from the current retrospective pilot study expand this research to include patients with renal impairment."
(11/23, Grasmo) reported that "research findings published in the International Journal of Clinical Oncology suggest that temsirolimus effectively stabilizes disease progression in patients with metastatic renal cell carcinoma (mRCC) undergoing hemodialysis." According to the article, "temsirolimus, a novel specific inhibitor of mammalian target of rapamycin, has previously been shown to exhibit an inhibitory effect on tumor cell growth and demonstrated significant overall and progression-free survival benefits compared with interferon (IFN)-alpha in patients with untreated poor-prognosis mRCC." Medwire noted that "the findings from the current retrospective pilot study expand this research to include patients with renal impairment."
Tumor Burden May Help Predict mRCC Prognosis. Medwire (11/23, Noel) reported that "tumor burden plays an independent prognostic and predictive role in metastatic renal cell carcinoma (mRCC)," according to the results of a clinical trial published Oct. 26 in the British Journal of Urology International. According to the article, "the trial comprised 124 patients, 66% of whom received either sorafenib or sunitinib, while 34% received placebo." The researchers found that found that "tumor burden (measured by RECIST 1.0) was directly and significantly related to progression-free survival (PFS) and overall survival (OS) even after adjusting for modified Memorial Sloan Kettering Cancer Centre (MSKCC) risk class and treatment." The noted that each "1-cm increase in tumor burden raised the risk for progression by 4.5% and the risk for death by 5.0%."
(11/23, Noel) reported that "tumor burden plays an independent prognostic and predictive role in metastatic renal cell carcinoma (mRCC)," according to the results of a clinical trial published Oct. 26 in the British Journal of Urology International. According to the article, "the trial comprised 124 patients, 66% of whom received either sorafenib or sunitinib, while 34% received placebo." The researchers found that found that "tumor burden (measured by RECIST 1.0) was directly and significantly related to progression-free survival (PFS) and overall survival (OS) even after adjusting for modified Memorial Sloan Kettering Cancer Centre (MSKCC) risk class and treatment." The noted that each "1-cm increase in tumor burden raised the risk for progression by 4.5% and the risk for death by 5.0%."
No comments:
Post a Comment